These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 396633)

  • 21. In vitro synergy studies using aztreonam and fluoroquinolone combinations against six species of Gram-negative bacilli.
    Critchley IA; Sahm DF; Kelly LJ; Karlowsky JA
    Chemotherapy; 2003 May; 49(1-2):44-8. PubMed ID: 12714810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interactions between antibacterial agents of the quinolone group and nitrofurantoin.
    Shah S; Greenwood D
    J Antimicrob Chemother; 1988 Jan; 21(1):41-8. PubMed ID: 3356622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An experimental analysis of the curative action of penicillin in acute bacterial infections. III. The effect of suppuration upon the antibacterial action of the drug.
    SMITH MR; WOOD WB
    J Exp Med; 1956 Apr; 103(4):509-22. PubMed ID: 13306859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biologically synthesized zinc oxide nanoparticles as nanoantibiotics against ESBLs producing gram negative bacteria.
    Maruthupandy M; Rajivgandhi G; Muneeswaran T; Song JM; Manoharan N
    Microb Pathog; 2018 Aug; 121():224-231. PubMed ID: 29807135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enterobacteria, beta-lactam antibiotics and beta-lactamases in clinical practice.
    Newsom SW; Marshall MJ; Harris AM
    J Med Microbiol; 1974 Nov; 7(4):473-82. PubMed ID: 4615152
    [No Abstract]   [Full Text] [Related]  

  • 26. Range of antibacterial activity of antibiotics at subminimal inhibitory concentrations: the ratio of minimal inhibitory concentration to minimal antibiotic concentration.
    Ezrow L; Saceanu C; Dabydeen H
    Rev Infect Dis; 1979; 1(5):821-4. PubMed ID: 396635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of antibiotics on bacterial structure and their pathogenicity.
    Lorian V; Ernst J
    Pathol Biol (Paris); 1987 Dec; 35(10 Pt 2):1370-6. PubMed ID: 3325898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of human extravascular temocillin concentrations simulated in an in-vitro kinetic model against beta-lactamase producing gram-negative bacilli.
    Cooper CE; White AR; Slocombe B
    J Antimicrob Chemother; 1991 Jan; 27(1):105-15. PubMed ID: 2050587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 6-(substituted methylene)penems, potent broad spectrum inhibitors of bacterial beta-lactamase. II. Racemic furyl and thienyl derivatives.
    Broom NJ; Coleman K; Hunter PA; Osborne NF
    J Antibiot (Tokyo); 1990 Jan; 43(1):76-82. PubMed ID: 2407709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cefepime shows good efficacy and no antibiotic resistance in pneumonia caused by Serratia marcescens and Proteus mirabilis - an observational study.
    Yayan J; Ghebremedhin B; Rasche K
    BMC Pharmacol Toxicol; 2016 Mar; 17():10. PubMed ID: 27004519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of cephalothin on growth patterns of micro-organisms.
    Bodey GP; Pan T
    J Antibiot (Tokyo); 1976 Oct; 29(10):1092-5. PubMed ID: 792494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antibacterial activity of mezlocillin and azlocillin/A survey (author's transl)].
    Knothe H
    Arzneimittelforschung; 1979; 29(12a):1916-20. PubMed ID: 120745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [In vitro antibacterial activity of a new parenteral penem, sulopenem].
    Yoshida T; Tateda E; Hiramatsu K; Yokota T
    Jpn J Antibiot; 1996 Apr; 49(4):324-37. PubMed ID: 8786624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibacterial action of combinations of oxytetracycline, dimethyl sulfoxide, and EDTA-tromethamine on Proteus, Salmonella, and Aeromonas.
    Wooley RE; Gilbert JP; Shotts EB
    Am J Vet Res; 1982 Jan; 43(1):130-3. PubMed ID: 6807142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minimal antibiotic concentrations of aminoglycosides and beta-lactam antibiotics for some gram-negative bacilli and gram-positive cocci.
    Lorian V; De Freitas CC
    J Infect Dis; 1979 May; 139(5):599-603. PubMed ID: 108345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of subinhibitory concentrations of cefotaxime on adhesion and polymorphonuclear leukocyte function with gram-negative bacteria.
    Bassaris HP; Lianou PE; Votta EG; Papavassiliou JT
    J Antimicrob Chemother; 1984 Sep; 14 Suppl B():91-6. PubMed ID: 6094466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rational choice of penicillins and cephalosporins based on parallel in-vitro and in-vivo tests.
    Selwyn S
    Lancet; 1976 Sep; 2(7986):616-9. PubMed ID: 61353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PS-5, a new beta-lactam antibiotic. III. Synergistic effects and inhibitory activity against a beta-lactamase.
    Okamura K; Sakamoto M; Fukagawa Y; Ishikura T; Lein J
    J Antibiot (Tokyo); 1979 Apr; 32(4):280-6. PubMed ID: 381269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In-vitro activity of ceftazidime, a beta-lactamase stable cephalosporin.
    Neu HC
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():131-4. PubMed ID: 19810175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recovery period and the exposure of bacteria to subminimal inhibitory concentrations of antibiotics.
    Kitzis MD; Bouanchaud DH; Acar JF
    Rev Infect Dis; 1979; 1(5):825-31. PubMed ID: 396636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.